How else does this happen when you look at an algorithmically created report on the studies and then find no physical evidence? It’s those algos again and some have learned how to work them as they can create a a visual used to be convincing for what ever the occasion calls for. 1900 instances sounds like quite a high number of studies that were not found actually conducted.
The article also states that the company may have “fixed” the results and if you read around here at the Quack often enough I talk algorithms created for “desired” and “accurate” results quite a and they should be the same, but not. When the physician evidence doesn’t match that’s a sure catch right there. When the FDA comes in they should have a complete open book, or set of algorithms to have the researchers verify. When you hear reports like this, no wonder we doubt some of the science that is out there today.
I know coders and developers get pushed to move faster to get a product to market and that is a deadly sin in more ways than one, you don’t push development on the software side until they are comfortable enough to test and re-test to feel confident enough that all bases have been covered as best they can. Kind of a side topic here we have an awful imbalance too in the US with social algorithms and biotech and funding is harder for research to get so again just a question as to is there yet one more factor with this type of action to move forward as quickly as possible? The last thing we want is “bad science”. BD
Good Science, Investments and The Chase for Social Algorithms Has Become a Dangerous Mix-Healthcare and The Creation of Jobs Continue to Suffer
WASHINGTON - Drug companies that had medicines tested by contractor Cetero Research might have to reevaluate results, U.S. regulators warned after the firm was found faking documents and manipulating samples.
The Food and Drug Administration said on Tuesday two 2010 inspections, an internal company investigation and a third-party audit uncovered "significant instances of misconduct and violations" at a Cetero facility in Houston.
The Cary, North Carolina-based firm does early-phase clinical research and bioanalytics for a number of drugmakers. The pharmaceutical companies can then use those studies as supporting evidence in drug approval applications to the FDA.